At the crowded MedtechPartners meeting on 7 March André van de Sande was presented by programme director Joep Welschen to the partners as the new chairman of the board of MedtechPartners. André succeeds Kest Huisman, who was chairman for the last ten years and is going to enjoy his well deserved retirement. Welschen stated that the board was very happy with Van de Sande and the added value of his broad experience, knowledge and big network in life sciences and health.
André van de Sande is a senior executive with 30 years of life sciences experience and a proven track record in both mature and emerging markets in Western and Central Europe, Asia Pacific and Africa. He led organisations ranging from 40 to 1.400 employees as CEO, Managing Director and as Regional Vice President. Most recently Van de Sande concluded the second exit of Life Science Consultancy company Xendo Holding. Since February 2019, he has his own Management Consultancy company and provides interim management, business coaching and has several board positions.